Application of natural product composition in preparation of medicine for preventing or treating azoospermia

Through the natural product composition composed of cyperonin and curcumin, the Nrf2/HO-1/HIF-1α pathway is coordinated, which solves the problems of spermatogenetic cells apoptosis and oxidative stress in azoospermia, and significantly improves sperm Quality and testicular tissue health provide a safer and more effective treatment option.

CN119074751AActive Publication Date: 2024-12-06JIANGSU HEALTH VOCATIONAL COLLEGE +1
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202411324453.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-23
Publication Date
2024-12-06
Estimated Expiration
2044-09-23

AI Technical Summary

Technical Problem

The prior art is difficult to effectively prevent and treat azoospermia, especially the problem of spermatogenesis apoptosis caused by oxidative stress, and there are limitations in single-target treatment of traditional synthetic drugs.

Method used

A natural product composition composed of Astragalin (AG) and Curcumin (CM) with a molar ratio of 1:1. As an oral or injectable dosage form drug, Nrf2/HO-1/HIF-1α is coordinated. pathways, inhibit spermatogenetic cell apoptosis, improve sperm quality and oxidative stress in testicular tissue.

Benefits of technology

In cell and animal experiments, sperm concentration, survival rate and motility status were significantly improved, oxidative stress levels in the testicles were reduced, and there were wider treatment windows and smaller toxic side effects compared with Western medicine.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119074751A_ABST
    Figure CN119074751A_ABST
Patent Text Reader

Abstract

The invention discloses application of a natural product composition in preparation of a medicine for preventing or treating azoospermia. The natural product composition is prepared from astragalus smicus glycoside and curcumin. The natural product composition composed of astragalus smicus glycoside and curcumin can inhibit spermatogenic cell apoptosis by synergistically regulating Nrf2 / HO-1 / HIF-1alpha and improve the azoospermia of rats, and compared with western medicines, the natural product composition is wider in therapeutic window and smaller in toxic and side effects and has application prospects in the medicine for preventing or treating azoospermia.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to application of a natural product composition in preparing a drug for preventing or treating azoospermia, and belongs to the field of medicine. Background Art

[0002] According to epidemiological statistics, by the end of the 20th century, infertility continued to affect 15% of couples worldwide, and it is still a sociological and medical issue related to global human development. According to research results, "male factors" account for about 40%, including asthenozoospermia and azoospermia, which are mainly related to sperm concentration, morphology and motility disorders. Among them, azoospermia (AZS) is one of the most common types of male infertility, which refers to a condition in which sperm motility in semen parameters is less than 42% or the number of sperm moving forward is less than 30%. Factors such as metabolic syndrome, drug induction and oxidative stress are the main pathogenesis of azoospermia. However, the mechanism of asthenozoospermia is complex and has not yet been clarified.

[0003] Under physiological conditions, the body's oxidation and antioxidant systems are in equilibrium, but factors such as metabolism or drugs can disrupt this balance, causing a sharp increase in the level of reactive oxygen in the body. Since sperm is susceptible to oxidative attack and lipid peroxidation of the plasma membrane, oxidative stress is often the main cause of azoospermia.

[0004] Nrf2 is an indispensable node in the body's antioxidant system. It can dissociate from keap1 and enter the nucleus, acting as a transcription factor to upregulate the body's antioxidant system. Studies have reported that Nrf2 can be used as a target to regulate spermatogenic cell apoptosis in rats with asthenozoospermia and treat asthenozoospermia. In related studies, mice with low Nrf2 expression can cause spermatogenic cell and sperm cell apoptosis in an Nrf2 / HO-1 / HIF-1α-dependent manner, leading to azoospermia. Therefore, regulating spermatogenic cell apoptosis using Nrf2 as a target is a feasible therapeutic strategy.

[0005] Therefore, more effective treatment strategies are urgently needed to prevent the occurrence and development of azoospermia. Different from the single target of synthetic small molecule drugs, traditional Chinese medicine and natural products have the advantages of multi-target and low toxicity, and have multi-pathway synergistic effects on the complex pathological changes of reproductive diseases, which may be a better choice to inhibit the development of azoospermia. Summary of the invention

[0006] The purpose of the present invention is to provide an application of a natural product composition in preparing a drug for preventing or treating azoospermia.

[0007] The technical solution for achieving the purpose of the present invention is as follows: The invention discloses an application of a natural product composition in preparing a drug for preventing or treating azoospermia. The natural product composition consists of astragalin (AG) and curcumin (CM).

[0008] Furthermore, in the natural product composition, the molar ratio or mass ratio of astragalus glycoside to curcumin is 1:1.

[0009] The dosage form of the drug for preventing or treating azoospermia of the present invention is an oral dosage form or an injection dosage form permitted in pharmaceutical science.

[0010] Furthermore, the drug for preventing or treating azoospermia also includes acceptable excipients.

[0011] Furthermore, the dosage of astragalus glycosides and curcumin was ≥20 mg kg -1 .

[0012] The present invention has found through experiments that at the cellular level, both CM and AG can inhibit Gc-1 cell apoptosis in a dose-dependent manner, and the combination of CM and AG can produce a synergistic inhibitory effect; at the animal level, CM and AG can synergistically improve the sperm concentration, sperm survival rate, sperm motility and serum sex hormone level of SD rats stimulated by cyclophosphamide (CP), and significantly reduce the oxidative stress level and spermatogenic cell apoptosis level of the testis of SD rats, and CM and AG can synergistically upregulate the expression level of Nrf2 and HO-1 in the testicular tissue of SD rats, and downregulate the expression level of HIF-1α. Therefore, the natural product composition composed of astragalus glycosides and curcumin can inhibit spermatogenic cell apoptosis by synergistically regulating Nrf2 / HO-1 / HIF-1α, improve rat azoospermia, and has a wider treatment window and less toxic side effects than Western medicine, and has application prospects in the prevention or treatment of azoospermia drugs. BRIEF DESCRIPTION OF THE DRAWINGS

[0013] Figure 1 The results of CM and AG in Example 1 on CCK-8 in mouse spermatogonia induced by H2O2 and the combined index results are shown in FIG. Figure 2 This is a diagram showing the effect of CM and AG in Example 2 on improving sperm parameters in azoospermia rats; Figure 3 The diagram is a diagram showing the improvement effect of CM and AG in Example 2 on the testicular tissue morphology of azoospermic rats, wherein Figure A is the result of H&E staining, Figure B is the number of spermatogenic cells, and Figure C is the number of interstitial cells; Figure 4 This is a diagram showing the improvement effect of CM and AG in Example 3 on the oxidative stress of testicular tissue in azoospermic rats; Figure 5The improvement effect of CM and AG in Example 3 on testicular tissue cell apoptosis in azoospermic rats; Figure 6 This is a schematic diagram of the immunohistochemical results of HIF-1α in the testicular tissue of azoospermic rats by CM and AG in Example 4; Figure 7 This is a schematic diagram of the results of CM and AG regulating the Nrf2 / HO-1 / HIF-1α pathway in the testicular tissue of azoospermic rats in Example 4; Figure 8 It is a schematic diagram of the molecular docking results of CM and AG on Nrf2 in Example 4, wherein Figure A is the CM structure, Figure B is the AG structure, Figure C is the docking result of CM and the Kelch domain of Keap1, and Figure D is the docking result of AG and the BTB domain of Keap1. DETAILED DESCRIPTION

[0014] The present invention is further described in detail below with reference to the accompanying drawings and examples. However, the technical solution of the present invention is not limited to the following embodiments. The experimental methods in the following examples are conventional methods unless otherwise specified; the materials, reagents, etc. used in the following examples are available from public commercial channels unless otherwise specified.

[0015] In the following examples, curcumin (CAS: 458-37-7) and astragaloside (CAS: 480-10-4) were purchased from Nanjing Yuanzhi Biotechnology Co., Ltd., the experimental cells were mouse spermatogonial cell line (Gc-1), and the experimental animals were SPF-grade SD rats.

[0016] Example 1: CM and AG synergistically inhibit H2O2-induced spermatogenic cell apoptosis.

[0017] Gc-1 cells were divided into 14 groups, each with three parallel wells, and 5*10 3Each cell was inoculated into a 96-well plate and cultured in DMEM high-glucose medium containing 10% fetal bovine serum in a 37°C incubator with 5% CO2. After inoculation, the three groups of cells were treated as follows: Group 1 was a blank control group (Con group), Group 2 was an H2O2 group with an H2O2 concentration of 200 μM / mL, Groups 3-6 and 7-10 were CM groups (2.5μM, 5μM, 10 μM and 20μM) and AG groups (2.5μM, 5μM, 10 μM and 20μM), respectively, with an H2O2 concentration of 200 μM / mL, and Groups 10-14 were CM and AG combined groups (CM+AG=2.5μM + 2.5μM, CM+AG=5μM + 5μM, CM+AG=10μM + 10μM, CM+AG=20μM + 20μM), and each group was treated for 24 h. After the above 14 groups of cells were treated as described above, new culture medium was replaced, CCK-8 was added, and the absorbance at 450 nm was measured by an enzyme marker to calculate the cell viability. The results are shown in Figure 1 AC. The overall results were imported into Compusyn software for combined exponential fitting, and the results are shown in Figure 1 As shown in DG.

[0018] Depend on Figure 1 The results of AC showed that both CM and AG could inhibit H2O2-induced apoptosis of Gc-1 cells in a dose-dependent manner, and the inhibitory effect of combined use on apoptosis was more significant; Figure 1 The results of DG showed that the combination of CM and AG in a molar ratio of 1:1 could produce a synergistic effect on cells.

[0019] Example 2: CM and AG synergistically improve sperm motility and testicular damage in azoospermic rats.

[0020] 75 SPF male SD rats weighing 210±5 g were selected. After adaptive feeding for 1 week, they were fasted for 12 h and CP was dissolved in 0.9% saline at a concentration of 35 mg kg -1 ·d -1 60 rats were randomly divided into 4 groups, 15 rats in each group, including model group (CP group), curcumin group (CM group), astragalus glycoside group (AG group) and combined group (CM+AG group). Each group was intraperitoneally injected with carboxymethylcellulose sodium (CMC-Na) solution, 20 mg·kg -1 ·d -1 Curcumin, 20 mg kg -1 ·d -1 Astragaloside and 20 mg kg-1 ·d -1 Curcumin +20 mg kg -1 ·d -1 Astragalus glycoside solution was used for continuous intervention for 14 days. During the experiment, all rats had free access to water and food, and the drugs were administered by gavage at a fixed time every day. The experiment was terminated after 21 days of intervention. After anesthesia, blood was collected from the abdominal aorta and bilateral testis and epididymal tissues were obtained. The left testis was fixed in 4% paraformaldehyde, and the right testis was frozen in a -80℃ refrigerator. The bilateral epididymis was placed in preheated Hams'F10 medium in a water bath and cultured at 37℃ for 30 min until the epididymal sperm was completely dissociated. The WLJY-9000 Weili digital color sperm quality detection system was used to detect sperm motility and kinematic parameters. Serum samples were taken and the expression of testosterone in rats was detected using an ELISA kit. Testicular tissue was taken, and the testicular damage of rats was detected using the H&E method, and then observed and photographed under an optical upright microscope.

[0021] Depend on Figure 2 It can be seen that the sperm motility, sperm count and sperm survival rate of the CP group were significantly lower than those of the Con group, while those of the CM and AG groups were significantly higher. The same was true for the examination results of sperm motility rate (VAP, VCL, VSL, STR and LIN). This shows that both CM and AG can improve the sperm quality of azoospermic rats. The sperm quality of rats in the CM+AG group was significantly better than that in the single-use group, indicating that CM and AG can synergistically improve the sperm quality of azoospermic rats. The results of sex hormone detection showed that CP could significantly reduce the expression of testosterone in rats, while CM and AG could reverse this phenomenon. CM and AG can synergistically increase the expression of testosterone in azoospermic rats. Figure 3 The H&E results showed that the testicular seminiferous tubules of rats in the CP group were significantly atrophied, the tubular spaces were enlarged, and the number of spermatogenic cells and spermatids was significantly reduced compared with the Con group. After drug intervention, the above situation was significantly alleviated. The seminiferous tubule spaces became smaller, the number of spermatogenic cells recovered, and the arrangement became more dense. The results of cell counting found that CM and AG can synergistically improve the number of spermatogenic cells and interstitial cells in the testicular tissue of azoospermic rats.

[0022] Example 3: CM and AG synergistically improve oxidative stress and spermatogenic cell apoptosis in testicular tissue of azoospermic rats.

[0023] The testicular tissue in Example 2 was ground by a tissue grinder and then subjected to determination of ROS, MDA, SOD, GSH and GSH-px. All determination methods were carried out according to the instructions of commercially available kits and detected in a multifunctional microplate reader.

[0024] After dewaxing, the paraffin sections of the testicular tissue in Example 2 were stained according to the instructions of the TUNEL staining kit and sealed with an anti-fluorescence quenching sealing solution. The staining results were immediately observed and photographed under an inverted fluorescence microscope, and the positive area (green fluorescence) was analyzed using ImageJ.

[0025] Depend on Figure 4 It can be seen that after CP intervention, the ROS and MDA levels in the testicular tissue of rats increased significantly, and the SOD level decreased significantly. After CM and AG intervention, the ROS and MDA levels in the testicular tissue decreased significantly, and the SOD level increased significantly, indicating that CM and AG can inhibit the oxidative stress of the testis of azoospermic rats. However, the inhibitory effect of single administration on oxidative stress is significantly weaker than that of combined administration, indicating that CM and AG can synergistically improve the oxidative stress of the testicular tissue of azoospermic rats.

[0026] Figure 5 The TUNEL staining results showed that CM and AG could synergistically improve the apoptosis of spermatogenic cells in the testicular tissue of azoospermic rats.

[0027] Example 4: CM and AG synergistically regulate Nrf2 / HO-1 / HIF-1α in azoospermic rats to inhibit spermatogenic cell apoptosis.

[0028] The testicular tissue in Example 2 was fixed in 4% paraformaldehyde fixative for 72 h, embedded in paraffin, and 5 μm sections were made. The paraffin sections were dewaxed using ethanol gradient elution, and after antigen repair and DNA denaturation, they were incubated in the dark for 30 min with 3% hydrogen peroxide solution to block endogenous peroxidase, and incubated at room temperature for 30 min with 3% BSA solution as blocking solution. The paraffin sections were mixed with the prepared rabbit HIF-1α primary antibody and placed in a humidified box for overnight incubation at 4°C. The mixed secondary antibody was prepared using HRP-labeled goat anti-rabbit IgG, the sections incubated with the primary antibody were placed in a humidified box, and the mixed secondary antibody was added to the section circle and incubated at room temperature for 1 h before DAB color development. After color development, the cell nuclei were counterstained with hematoxylin, the staining was observed under a microscope after sealing with glycerol, and the positive area was analyzed using ImageJ.

[0029] The testicular tissue in Example 2 was washed twice with PBS, and then lysed with RIPA lysis solution containing 1mmol / LPMSF (100 microliters of RIPA lysis solution was added for every 10mg of tissue). After grinding with a tissue grinder for 5min, the cells were lysed on ice for 30min. After BCA quantification, the loading buffer was added and denatured in a constant temperature metal bath at 100°C for 10min, and the protein expression was detected by Western Bolting method. 30 μg of protein was loaded on a 10% SDS-PAGE gel, and the position of the target protein was cut and transferred to a PVDF membrane after constant voltage electrophoresis of 80V-30min and 120V-55min. After the PVDF membrane was blocked by incubation on a shaker at room temperature with 5% BSA for 2h, it was incubated with the primary antibody (1:1000) at 4°C overnight. After washing with TBST the next day, it was incubated at room temperature with a secondary antibody labeled with horseradish peroxidase (1:2000) for 2h, and after washing, it was imaged in a gel imaging system using ECL luminescent liquid.

[0030] The structural formulas of CM and AG were obtained from the PubChem database (https: / / pubchem.ncbi.nlm.nih.gov / ), and the protein structure of Nrf2 was obtained from the PDB database (RCSB PDB, https: / / www.rcsb.org / ). The binding sites of two different domains of Keap1, a negative regulator of Nrf2, were taken, including the BTB domain and the Kelch domain. Autodocktools 1.5.6 was used for protein structure processing and Autodocking vina 1.2.0 was used for molecular docking. The docking results were imported into Pymol for visualization.

[0031] Figure 6 A is a schematic diagram of the immunohistochemical results of HIF-1α in rat testicular tissue, and B is a schematic diagram of the positive area quantification results. CM and AG can synergistically reduce the expression of HIF-1α in the testicular tissue of azoospermic rats.

[0032] Figure 7 A is a schematic diagram of WB results, B is the expression quantification diagram of Nrf2, C is the expression quantification diagram of HO-1, and D is the expression quantification diagram of HIF-1α. The results show that CM and AG can synergistically restore the Nrf2 / HO-1 / HIF-1α pathway in the testicular tissue of azoospermic rats.

[0033] Figure 8Figure 1 is the structural formula of CM (A) and AG (B), C is the docking diagram of CM and Keap1 Kelch domain, and its binding energy is -8.3 kJ / mol, and D is the docking diagram of AG and Keap1 BTB domain, and its binding energy is -6.2 kJ / mol. The results show that the synergistic effect of CM and AG may be achieved by inhibiting Keap1 expression and activity through different binding sites and synergistically upregulating Nrf2.

Claims

1. Use of a natural product composition in the preparation of a drug for preventing or treating azoospermia, characterized in that: The natural product composition consists of astragalus glycoside and curcumin.

2. The use according to claim 1, characterized in that: In the natural product composition, the molar ratio or mass ratio of astragaloside to curcumin is 1:

1.

3. The use according to claim 1, characterized in that: The dosage form of the drug for preventing or treating azoospermia is an oral dosage form or an injection dosage form.

4. The use according to claim 1, characterized in that: The drug for preventing or treating azoospermia also includes excipients.

5. The use according to claim 1, characterized in that: The dosage of astragalus glycosides and curcumin was ≥20 mg kg -1 .

Citation Information

Patent Citations

  • Application of astragalin in preparation of drug for treating diabetic testicular dysfunction

    CN109091488A

  • Application of curcumin in preparation of medicine for preventing and treating ionizing radiation induced reproductive system injury

    CN114533710A